drugset / Trial / NCT00726687

Phase 1b Study of Indibulin in Combination With Capecitabine in Advanced Solid Tumors

NCT00726687

Phase 1/2 Unknown 7 enrolled Alaunos Therapeutics
NaSingle-groupOpen-labelTreatment

Summary

This is a phase 1b study of Indibulin in combination with Capecitabine in advanced solid tumors.

Timeline

Start
2008-06
Primary completion
2013-06
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 875 mg/m2 Oral
Subject Capecitabine Small molecule 1250 mg/m2 Oral
Subject indibulin Small molecule 400 mg Oral
Subject indibulin Small molecule 600 mg Oral

Indications